These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37812385)

  • 1. Lysine-Specific Demethylase 1 (LSD1) Inhibitors: Peptides as an Emerging Class of Therapeutics.
    Baby S; Shinde SD; Kulkarni N; Sahu B
    ACS Chem Biol; 2023 Oct; 18(10):2144-2155. PubMed ID: 37812385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.
    Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM
    Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials.
    Noce B; Di Bello E; Fioravanti R; Mai A
    Front Pharmacol; 2023; 14():1120911. PubMed ID: 36817147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
    Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
    J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures.
    Ota Y; Kakizawa T; Itoh Y; Suzuki T
    Molecules; 2018 May; 23(5):. PubMed ID: 29734782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive
    Sacilotto N; Dessanti P; Lufino MMP; Ortega A; Rodríguez-Gimeno A; Salas J; Maes T; Buesa C; Mascaró C; Soliva R
    ACS Pharmacol Transl Sci; 2021 Dec; 4(6):1818-1834. PubMed ID: 34927013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances of LSD1/KDM1A inhibitors for disease therapy.
    Zhang C; Wang Z; Shi Y; Yu B; Song Y
    Bioorg Chem; 2023 May; 134():106443. PubMed ID: 36857932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer Drugs of Lysine Specific Histone Demethylase-1 (LSD1) Display Variable Inhibition on Nucleosome Substrates.
    Senanayaka D; Zeng D; Deniz E; Priyankara IK; Helmbreck J; Schneider O; Mardikar A; Uren A; Reiter NJ
    Biochemistry; 2024 Jun; 63(11):1369-1375. PubMed ID: 38742921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
    Zhang S; Liu M; Yao Y; Yu B; Liu H
    Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models.
    Jasmine S; Mandl A; Krueger TEG; Dalrymple SL; Antony L; Dias J; Celatka CA; Tapper AE; Kleppe M; Kanayama M; Jing Y; Speranzini V; Wang YZ; Luo J; Trock BJ; Denmeade SR; Carducci MA; Mattevi A; Rienhoff HY; Isaacs JT; Brennen WN
    Prostate; 2024 Jul; 84(10):909-921. PubMed ID: 38619005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators.
    Itoh Y; Aihara K; Mellini P; Tojo T; Ota Y; Tsumoto H; Solomon VR; Zhan P; Suzuki M; Ogasawara D; Shigenaga A; Inokuma T; Nakagawa H; Miyata N; Mizukami T; Otaka A; Suzuki T
    J Med Chem; 2016 Feb; 59(4):1531-44. PubMed ID: 26700437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy.
    Shen L; Wang B; Wang SP; Ji SK; Fu MJ; Wang SW; Hou WQ; Dai XJ; Liu HM
    J Med Chem; 2024 Jan; 67(2):922-951. PubMed ID: 38214982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
    Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
    Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
    Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
    Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
    Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
    Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors.
    Culhane JC; Wang D; Yen PM; Cole PA
    J Am Chem Soc; 2010 Mar; 132(9):3164-76. PubMed ID: 20148560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.
    Kakizawa T; Ota Y; Itoh Y; Suzuki T
    Bioorg Med Chem Lett; 2018 Jan; 28(2):167-169. PubMed ID: 29198865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysine-specific demethylase 1-mediated demethylation of histone H3 lysine 9 contributes to interleukin 1β-induced microsomal prostaglandin E synthase 1 expression in human osteoarthritic chondrocytes.
    El Mansouri FE; Nebbaki SS; Kapoor M; Afif H; Martel-Pelletier J; Pelletier JP; Benderdour M; Fahmi H
    Arthritis Res Ther; 2014 May; 16(3):R113. PubMed ID: 24886859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Structure-Activity Relationship Study of SNAIL1 Peptides as Inhibitors of Lysine-Specific Demethylase 1.
    Takada Y; Adachi K; Fujinaga Y; Yamashita Y; Itoh Y; Suzuki T
    Chem Pharm Bull (Tokyo); 2024; 72(2):155-160. PubMed ID: 38296557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1 .
    Mimasu S; Umezawa N; Sato S; Higuchi T; Umehara T; Yokoyama S
    Biochemistry; 2010 Aug; 49(30):6494-503. PubMed ID: 20568732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.